Art

J-GLOBAL ID：202002229894952361   Reference number：20A2527796

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

KRAS野生型転移性結腸直腸癌における三次治療としてのイリノテカン+セツキシマブ再菌血症の第2相試験:JACCRO CC-08【JST・京大機械翻訳】

Author (22)： Masuishi Toshiki (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan) ,  Masuishi Toshiki (Department of Gastroenterology, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan) ,  Tsuji Akihito (Department of Medical Oncology, Kagawa University Hospital, Kita-gun, Kagawa, Japan) ,  Kotaka Masahito (Gastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, Japan) ,  Nakamura Masato (Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Nagano, Japan) ,  Kochi Mitsugu (Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan) ,  Takagane Akinori (Department of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan) ,  Shimada Ken (Department of Internal Medicine, Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan) ,  Denda Tadamichi (Department of Gastroenterology, Chiba Cancer Center, Chuo-ku, Chiba, Japan) ,  Segawa Yoshihiko (Department of Medical Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan) ,  Tanioka Hiroaki (Clinical Oncology, Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan) ,  Hara Hiroki (Department of Gastroenterology, Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan) ,  Sagawa Tamotsu (Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan) ,  Watanabe Takanori (Department of Surgery, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan) ,  Takahashi Takao (Department of Surgical Oncology, Gifu University, Graduate School of Medicine, Gifu, Japan) ,  Negoro Yuji (Department of Gastroenterology, Kochi Health Sciences Center, Kochi, Japan) ,  Manaka Dai (Department of Surgery, Kyoto Katsura Hospital, Nishikyo-ku, Kyoto, Japan) ,  Fujita Hideto (Department of Digestive Surgery, Kanazawa Medical University Hospital, Kahoku-gun, Ishikawa, Japan) ,  Suto Takeshi (Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan) ,  Takeuchi Masahiro (Department of Clinical Medicine (Biostatistics), Kitasato University School of Pharmacy, Minato-ku, Tokyo, Japan) ,  Ichikawa Wataru (Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan) ,  Fujii Masashi (Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan)
Material： British Journal of Cancer
Volume： 123  Issue： 10  Page： 1490-1495  Publication year： 2020 
JST Material Number： C0922B  ISSN： 0007-0920  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Abstract/Point： Abstract: Background: Regoraf...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2527796&from=J-GLOBAL&jstjournalNo=C0922B") }}

Thesaurus term： Bacteremia ,  clinical trial ,  effectiveness ,  *wild type ,  *phase 2 study ,  randomized controlled trial ,  *K-ras ,  end point ,  progression-free survival ,  molecular targeting drug
Semi thesaurus term： *転移性大腸癌 ,  *セツキシマブ ,  再投与 ,  全生存率 , 【Automatic Indexing@JST】

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (2)： Regorafenib ,  5-(Trifluoromethyl)-2′-deoxyuridine/5-chloro-6-[(2-iminopyrrolizino)methyl]uracil

Terms in the title (8)： KRAS ,  野生型 ,  転移性結腸直腸癌 ,  治療 ,  イリノテカン ,  セツキシマブ ,  菌血症 ,  第2相試験